2025.06.19本文字数:3364,阅读时长大约8.5分钟导读:全球制药格局风云变幻,默沙东的K药面临专利悬崖与GLP-1类药物的双重挑战,肿瘤、自免、代谢三大领域竞争加剧。谁能成为创新药界的下一位霸主?这场“混战”充满悬念,产品力、管线厚度与战略决策成为关键。在短短一周时间(6月7日至12日)内,默沙东的帕博利珠单抗皮下注射制剂(MK-3475A)便在CDE提交了24条上市申请并获得受理,其...
Source Link2025.06.19本文字数:3364,阅读时长大约8.5分钟导读:全球制药格局风云变幻,默沙东的K药面临专利悬崖与GLP-1类药物的双重挑战,肿瘤、自免、代谢三大领域竞争加剧。谁能成为创新药界的下一位霸主?这场“混战”充满悬念,产品力、管线厚度与战略决策成为关键。在短短一周时间(6月7日至12日)内,默沙东的帕博利珠单抗皮下注射制剂(MK-3475A)便在CDE提交了24条上市申请并获得受理,其...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.